Proteomics based markers of clinical pain severity in juvenile idiopathic arthritis.

Autor: Van Der Heijden H; Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.; Faculty of Psychology and Neuroscience, Section Neuropsychology & Psychopharmacology Maastricht University, Maastricht, The Netherlands.; Faculty of Science, Biomedical Sciences Neurobiology, University of Amsterdam, Amsterdam, The Netherlands., Fatou B; Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Sibai D; Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Hoyt K; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Taylor M; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Cheung K; BioSAS Consulting, Inc, Wellesley, MA, USA., Lemme J; Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Cay M; Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Goodlett B; Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Lo J; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Hazen MM; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Halyabar O; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Meidan E; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Schreiber R; Faculty of Psychology and Neuroscience, Section Neuropsychology & Psychopharmacology Maastricht University, Maastricht, The Netherlands., Jaimes C; Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Ecklund K; Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Henderson LA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Chang MH; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Nigrovic PA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Sundel RP; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Steen H; Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. hanno.steen@childrens.harvard.edu.; Neurobiology Program, Boston Children's Hospital, Boston, MA, USA. hanno.steen@childrens.harvard.edu.; Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA. hanno.steen@childrens.harvard.edu., Upadhyay J; Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. jaymin.upadhyay@childrens.harvard.edu.; Department of Psychiatry, McLean Hospital, Harvard Medical School, MA, Belmont, USA. jaymin.upadhyay@childrens.harvard.edu.
Jazyk: angličtina
Zdroj: Pediatric rheumatology online journal [Pediatr Rheumatol Online J] 2022 Jan 15; Vol. 20 (1), pp. 3. Date of Electronic Publication: 2022 Jan 15.
DOI: 10.1186/s12969-022-00662-1
Abstrakt: Introduction: Juvenile idiopathic arthritis (JIA) is a cluster of autoimmune rheumatic diseases occurring in children 16 years of age or less. While it is well-known that pain may be experienced during inflammatory and non-inflammatory states, much remains ambiguous regarding the molecular mechanisms that may drive JIA pain. Thus, in this pilot study, we explored the variability of the serum proteomes in relation to pain severity in a cohort of JIA patients.
Methods: Serum samples from 15 JIA patients (male and female, 12.7 ± 2.8 years of age) were assessed using liquid chromatography/mass spectrometry (LC/MS). Correlation analyses were performed to determine the relationships among protein levels and self-reported clinical pain severity. Additionally, how the expression of pain-associated proteins related to markers of inflammation (Erythrocyte Sedimentation Rate (ESR)) or morphological properties of the central nervous system (subcortical volume and cortical thickness) implicated in JIA were also evaluated.
Results: 306 proteins were identified in the JIA cohort of which 14 were significantly (p < 0.05) associated with clinical pain severity. Functional properties of the identified pain-associated proteins included but were not limited to humoral immunity (IGLV3.9), inflammatory response (PRG4) and angiogenesis (ANG). Associations among pain-associated proteins and ESR (IGHV3.9, PRG4, CST3, VWF, ALB), as well as caudate nucleus volume (BTD, AGT, IGHV3.74) and insular cortex thickness (BTD, LGALS3BP) were also observed.
Conclusions: The current proteomic findings suggest both inflammatory- and non-inflammatory mediated mechanisms as potential factors associated with JIA pain. Validation of these preliminary observations using larger patient cohorts and a longitudinal study design may further point to novel serologic markers of pain in JIA.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje